

# INTEGRATED PROTEINS LIMITED

City Point, 5<sup>th</sup> Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: [ipl.complianceofficer@gmail.com](mailto:ipl.complianceofficer@gmail.com)

Website: [www.integratedproteins.com](http://www.integratedproteins.com)

CIN: L15400GJ1992PLC018426

Ref: IPL/BSE/Outcome of BM

Date: 9<sup>th</sup> February, 2021

To,  
Department of Corporate Service  
BSE Limited  
PhirozJeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

Sub: Outcome of Board Meeting

Ref : Scrip Code - 519606

Respected Sir / Madam,

Pursuant to the provisions of SEBI(LODR), 2015, we hereby report the outcome of the meeting of the Board of Directors held today i.e. on 9th February, 2021.

The Board at its meeting held today, considered, and approved the following items:

1. Considered, approved the unaudited financial results for the quarter ended December, 2020 along with the Limited Review Report by M/s DGMS and Co, Statutory Auditors.

You are requested to take above on your records.

Thanking you in anticipation.

FOR, INTEGRATED PROTEINS LIMITED

Piyush C. Vora  
Director & CFO (DIN: 00296074)

# INTEGRATED PROTEINS LIMITED

CIN:L15400GJ1992PLC018426

Registered Office: 5TH Floor, City Point, Opp. Town Hall, Jamnagar, Gujarat-361001

## Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31 December, 2020

(Rs. In Lakh except per share data)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
A Date of start of reporting period	01/10/2020	01/07/2020	01/10/2019	01/04/2020	01/04/2019	01/04/2019
B Date of end of reporting period	31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
C Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Part I</b>						
<b>I Revenue From Operations</b>						
Net sales or Revenue from Operations	-	-	-	-	-	-
<b>II Other Income</b>	3.93	3.95	4.06	11.96	12.20	16.43
<b>III Total Revenue (I + II)</b>	3.93	3.95	4.06	11.96	12.20	16.43
<b>IV Expenses</b>						
(a) Cost of materials consumed	-	-	-	-	-	-
(b) Purchases of stock-in-trade	-	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
(d) Employee benefit expense	0.60	0.48	0.62	1.62	1.56	5.77
(e) Finance Costs	-	-	-	-	-	-
(f) Depreciation and amortisation expense	0.72	0.72	0.72	2.16	2.16	2.88
(g) Other Expenses	0.17	2.58	0.94	6.16	4.88	5.93
<b>Total expenses</b>	1.49	3.78	2.28	9.94	8.60	14.58
<b>V Profit (loss) before Exceptional and</b>	2.44	0.17	1.78	2.02	3.60	1.85
<b>VI Exceptional items</b>	-	-	-	-	-	-
<b>VII Profit (loss) before Tax (VII-VIII)</b>	2.44	0.17	1.78	2.02	3.60	1.85
<b>VIII Tax Expense</b>	0.74	(0.10)	0.34	0.54	0.60	1.29
(a) Current Tax	0.85	-	0.44	0.85	0.90	0.87
(Less):- MAT Credit	-	-	-	-	-	-
Current Tax Expense Relating to Prior years	-	-	-	-	-	-
(b) Deferred Tax (Asset)/Liabilities	(0.11)	(0.10)	(0.10)	(0.31)	(0.30)	0.42
<b>IX Net Profit/Loss for the period from Continuing Operations (IX-X)</b>	1.70	0.27	1.44	1.48	3.01	0.56
<b>X Profit (Loss) from Discontinuing Operations</b>	-	-	-	-	-	-
<b>XI Tax Expenses of Discontinuing Operations</b>	-	-	-	-	-	-
<b>XII Net Profit (Loss) from Discontinuing Operations after tax (XII-XIII)</b>	-	-	-	-	-	-
<b>XIII Profit (Loss) for the period (XI+XIV)</b>	1.70	0.27	1.44	1.48	3.01	0.56
<b>XIV Other Comprehensive Income</b>						
a. i). Amount of item that will not be reclassified to profit or loss	-	-	-	-	-	-
ii). Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
b i). Item that will be reclassified to profit or loss	-	-	-	-	-	-
ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>XV Total Comprehensive income</b>	-	-	-	-	-	-
<b>Total Comprehensive income [Comprising Profit for the Period (After tax) and Other comprehensive income] (XV+XVII)</b>	1.70	0.27	1.44	1.48	3.01	0.56
<b>XVI Details of equity share capital</b>						
Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	352.02	352.02	352.02	352.02	352.02	352.02
Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
<b>XVII Reserves excluding revaluation reserve as per Balance Sheet</b>						
<b>XVIII Earnings per share (Not Annualized for Quarter ended)</b>						
(a) Earnings per share Continuing Operation ( Not Annualised for Quarter ended )						
Basic earnings per share before extraordinary items	0.05	0.01	0.04	0.05	0.09	0.02
Diluted earnings per share before extraordinary items	0.05	0.01	0.04	0.05	0.09	0.02
(b) Earnings per share Discontinuing Operation ( Not Annualised for Quarter ended )						
Basic earnings per share after extraordinary items	-	-	-	-	-	-
Diluted earnings per share after extraordinary items	-	-	-	-	-	-
(c) Earnings per share ( Not Annualised for Quarter ended )						
Basic earnings per share before extraordinary items	0.05	0.01	0.04	0.05	0.09	0.02
Diluted earnings per share before extraordinary items	0.05	0.01	0.04	0.05	0.09	0.02






**Independent Auditor's Review Report On Quarterly Financial Results of the Company**  
**Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure**  
**Requirement) Regulations, 2015**

**Review Report to**  
**The Board of Directors of**  
**INTEGRATED PROTEINS LIMITED,**

1. We have reviewed the accompanying statement of standalone unaudited financial results of Integrated Proteins Limited ('the Company') for the quarter ended December 31, 2020 ('the Statement') being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement of principles laid done in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our Responsibility is to issue a report on the statement based on our review.
3. We conducted our Review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standards requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable



**Sarvesh A. Gohil**

B.Com., F.C.A.

us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For, D. G. M. S. & Co.  
Chartered Accountants  
FRN: 0112187W

Sarvesh A. Gohil  
Partner

Membership No. 135782

UDIN: 21135782 AAAAEZ2011

Date: 09.02.2021

Place: Jamnagar